BEAM — Q2 2026 Financial Report Analysis

Q2 2026: a quiet quarter on revenue, with the money going into two late-stage programs

Beam Therapeutics is a clinical-stage biotech: it sells no medicines yet. It develops "base editing", a form of gene editing that changes a single DNA letter without cutting both strands of the DNA. Its income comes from partners who license its technology, and in the second quarter that income nearly disappeared: license and collaboration revenue fell to $0.5 million from $8.5 million a year earlier, which the company attributes to "a change in the level of research activities on our license and collaboration programs." Operating costs were roughly flat at $127.0 million, so the net loss widened 20% to $122.7 million, or $1.18 per share (Q2 2025: $102.1 million, $1.00).

For a company at this stage, the financial statements matter mostly for one question: how long the cash lasts relative to the next clinical and regulatory milestones. Beam ended June with $1.15 billion in cash and investments and says that, together with $200 million it expects to borrow later, this funds operations into mid-2029.

At a glance

• $0.5 million in revenue (down 94%). Partner research work has wound down; the six-month figure ($32.2 million) is held up by a single $25.0 million milestone payment from Eli Lilly booked in Q1.
• $122.7 million net loss (20% wider). Costs barely moved; the wider loss came from the missing partner revenue and about $14 million less in non-operating income.
• $1.15 billion of cash and investments. Down $92 million from December even after a new $100 million loan, so the underlying six-month draw on cash was about $185 million.

Key figures

An operating margin is not shown: with revenue of $0.5 million against $127 million of costs, the ratio is a meaningless number in the tens of thousands of percent.

Takeaway: Beam's revenue line is no longer a guide to anything; the business now runs on its balance sheet. Its mid-2029 runway assumes another $200 million from its Sixth Street credit facility, and under the loan agreement most of that facility's further money is tied to the sickle cell therapy risto-cel: $100 million when the FDA accepts its application, $100 million on approval and $100 million on hitting a sales target (a last $100 million needs the lenders' agreement). The runway and the regulatory timetable are effectively the same bet.

Where the money went

R&D fell 6.5% to $95.1 million, but not because Beam is doing less. The main decline was an $8.4 million drop in external R&D (outsourced manufacturing and clinical work), which the filing attributes "primarily [to] the timing of manufacturing and clinical activities" — timing, which tends to reverse. Stock-based compensation in R&D also fell $3.6 million because one-time stock awards from prior years have stopped being expensed. Moving the other way, employee costs rose $4.3 million as the R&D headcount grew from 401 to 420.

Over the full six months, R&D was flat ($199.6 million vs. $200.6 million), but inside that, "other" R&D expense jumped $11.9 million to $13.0 million, which the company ties to "milestone and non-royalty sublicense activity" — payments Beam owes to the owners of technology it licenses in, which tend to come due as programs advance.

G&A rose 18.9% to $31.9 million. Employee and consultant costs added $4.9 million (G&A staff grew from 108 to 120) and legal costs $1.2 million; over six months legal spending is up $6.6 million. The company describes part of G&A as "commercial readiness", which fits a business preparing to file for its first approval by year-end.

What the headline numbers hide

• The six-month revenue increase is a one-off. First-half revenue doubled to $32.2 million, but $25.0 million of that is a single milestone under Beam's agreement with Eli Lilly (which took over Beam's rights in Verve Therapeutics' cardiovascular programs). Strip it out and first-half revenue fell to about $7.2 million from $15.9 million. Deferred revenue — partner money received in advance and recognized as work is done — went from $6.7 million at year-end to zero, so there is no backlog of recurring collaboration revenue left on the balance sheet. Further revenue depends on new milestones or new deals.
• Part of the wider loss is non-cash and tied to Beam's own share price. Beam owes Harvard and the Broad Institute "success payments" (up to $90 million each) if its stock price rises past set levels. Accounting re-values that obligation every quarter: this quarter it produced a $4.2 million expense, against a $1.3 million gain a year earlier, a $5.5 million swing. Equity-investment gains also fell $4.1 million. Neither says anything about the underlying business.
• Interest income is shrinking and a new interest bill has started. "Interest and other income, net" fell to $7.5 million from $12.3 million. Part of that is the new loan: Beam drew $100 million from Sixth Street Lending Partners in February at an effective interest rate of 10.5%, and recorded $2.7 million of interest expense on it in Q2. Borrowing at 10.5% while holding cash that earns less is the price of extending the runway without selling new shares.
• Cash burn is higher than the loss suggests in one way, lower in another. The six-month operating cash outflow ($194.6 million) was smaller than the net loss ($217.0 million), mostly because $38.3 million of stock-based compensation is a real cost to shareholders (it dilutes them) but not a cash payment. Against that, Beam paid down $14.9 million of accrued expenses and used up the $6.7 million of deferred revenue. The underlying pace is roughly $95–100 million of cash a quarter, before any increase from late-stage trials.
• No new shares were sold in the half. Beam made no sales under its at-the-market equity program in the first six months (it has $864.0 million of gross sales to date out of a $1.1 billion authorization). The share count rose only modestly, to 103.3 million from 101.7 million, mostly from employee option exercises. This is why the per-share loss widened a little less (18%) than the total loss (20%) — and why, over six months, loss per share actually shrank to $2.09 from $2.21: the March 2025 share offering means the six-month comparison is against a smaller average share count.

The pipeline that the spending pays for

Beam's spending is concentrated on two programs that could reach regulators within roughly two years:

• Risto-cel (sickle cell disease). A one-time treatment in which a patient's own blood stem cells are edited outside the body and re-infused after chemotherapy conditioning (busulfan). Dosing is complete for all adult and adolescent patients in the roughly 50-patient BEACON trial. Data published in the New England Journal of Medicine in April 2026 showed mean fetal hemoglobin (a form of hemoglobin that prevents red blood cells from sickling) above 60%, and no investigator-reported severe vaso-occlusive crises (the painful blockages that define the disease) after engraftment. One patient died four months after infusion from respiratory failure the investigator judged likely related to busulfan, not risto-cel. Beam expects updated data and a BLA (the formal application to the FDA to approve a biologic medicine) as early as year-end 2026.
• BEAM-302 (alpha-1 antitrypsin deficiency, AATD). An inherited disease in which a faulty protein builds up in the liver and leaves the lungs unprotected. BEAM-302 is a one-time infusion that edits liver cells directly inside the body. At the 60 mg dose chosen for the next stage, mean total AAT reached 16.1 µM, the faulty Z-AAT protein fell 84%, and 94% of circulating AAT was the corrected form (data as of February 10, 2026). Single doses were well tolerated up to 75 mg; in a small three-patient cohort given two doses, one patient had a Grade 4 liver-enzyme (ALT) elevation, which was asymptomatic. After FDA feedback, Beam is pursuing accelerated approval — approval based on a lab measure (AAT levels over 12 months) that is reasonably likely to predict clinical benefit — and dosed the first of about 50 patients in the pivotal cohort in July 2026.

Earlier-stage programs: BEAM-301 (glycogen storage disease Ia) has initial data expected in 2026; BEAM-304 (phenylketonuria) received FDA clearance to begin human trials in June 2026; and work continues on delivering editors to blood stem cells directly inside the body, which would avoid chemotherapy conditioning.

Outlook

Management's guidance: cash, cash equivalents and marketable securities at June 30, plus an expected additional $200 million from the Sixth Street facility, fund operations "into mid-2029", covering the risto-cel launch, the BEAM-302 pivotal plan and clinical proof of concept for BEAM-304. The 10-Q also says operating expenses are expected to increase over the next twelve months as BLA-readiness activities ramp up.

Our read: the quarter's financials hold no surprises for a company at this stage — flat costs, partner revenue fading, a balance sheet doing the work. What changes the picture in the next six months is regulatory, not financial: (1) whether the risto-cel BLA is filed on the year-end timeline, since FDA acceptance of it is the condition for the next $100 million loan draw; (2) the updated BEAM-302 data presented at the European Respiratory Society Congress in September, which came after this filing and is not covered here; and (3) initial BEAM-301 data promised for 2026. If the BLA slips into 2027, the mid-2029 runway likely shortens or requires selling new shares, which Beam has avoided so far this year. Next quarter to watch: whether external R&D rises again as the "timing" effect reverses and the 50-patient BEAM-302 pivotal cohort enrolls.

Source: Beam Therapeutics Form 10-Q for the quarter ended June 30, 2026 (filed August 4, 2026) and the accompanying earnings release (Exhibit 99.1 to Form 8-K, August 4, 2026).